Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase

Cancer

Volumn 110, Issue 12, 2007, Pages 2709-2715

  Xie, Wanling ^a   Nakabayashi, Mari ^a   Regan, Meredith M ^a   Oh, William K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Alkaline phosphatase; Bone metastases; Hormone refractory prostate cancer; Prostate specific antigen; Survival

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; DOCETAXEL; EPOTHILONE B; ESTRAMUSTINE; IMATINIB; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 37049020294     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23111     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Cho D, Di Blasio CJ, Rhee AC, et al. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol. 2003;21:282-291.
3. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.
4. Kelly WK, Scher HI, Mazumdar M, et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11:607-615.
5. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-3982.
6. Oh WK, Hayes J, Evan C, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006;5:61-66.
7. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998;279:1709-1714.
8. Cook RJ, Coleman R, Brown J, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12:3361-3367.
9. Huggins C, Hodges CV Studies in prostate cancer. I. The effect of estrogen and androgen in injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:243.
10. Wajsman Z, Chu TM, Bross D, et al. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma. J Urol. 1978;119:244-246.
11. Fontana A, Delmas PD. Markers of bone turnover in bone metastases. Cancer. 2000;88:2952-2960.
12. Posen S, Doherty E. The measurement of serum alkaline phosphatase in clinical medicine. Adv Clin Chem. 1981;22:163-245.
13. Price CP. Multiple forms of human serum alkaline phosphatase: detection and quantitation. Ann Clin Biochem. 1993;30(pt 4):355-372.